NCT06102512View on ClinicalTrials.gov

A Study of [14C]-LOXO-783 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

October 23, 2023

Primary Completion Date

December 23, 2023

Study Completion Date

January 17, 2024

Conditions

Healthy

Interventions

DRUG

[¹⁴C]-LOXO-783

Administered orally

DRUG

LOXO-783

Administered orally

DRUG

[¹⁴C]-LOXO-783

Administered IV

Trial Locations (1)

53704

Fortrea Clinical Research, Madison

Sponsors

Collaborators (1)

Loxo Oncology, Inc.

All Listed Sponsors

collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT06102512 - A Study of [14C]-LOXO-783 in Healthy Adult Participants | Biotech Hunter | Biotech Hunter